The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== Kuwaiti resistance movement === Kuwaitis founded a local armed resistance movement following the Iraqi occupation of Kuwait. The Kuwaiti resistance's casualty rate far exceeded that of the coalition military forces and Western hostages. The resistance predominantly consisted of ordinary citizens who lacked any form of training and supervision.
=== Deprotecting carbamates === Some carbamate protecting groups such as carboxybenzyl (Cbz) or allyloxycarbonyl (alloc) can be deprotected using 2-mercaptoethanol in the presence of potassium phosphate in dimethylacetamide.
While BIA Separations was the first to commercially market polymeric monoliths, Merck KGaA was the first company to market silica monoliths. In 1996, Tanaka and coworkers at the Kyoto Institute of Technology published extensive work on silica monolith technologies. Merck was later issued a license from Kyoto Institute of Technology to develop and produce the silica monoliths. Promptly thereafter, in 2001, Merck introduced its Chromolith line of monolithic HPLC columns at analytical instrumentation trade show PittCon. Initially, says Karin Cabrera, senior scientist at Merck, the high flow rate was the selling point for the Chromolith line. Based on customer feedback, though, Merck soon learned that the columns were more stable and longer-lived than particle-packed columns. The columns were the recipients of various new product awards. Difficulties in production of the silica monoliths and tight patent protection have precluded attempts by other companies at developing a similar product. It has been noted that there are more patents concerning how to encapsulate the silica rod than there are on the manufacture of the silica itself. Historically, Merck has been known for its superior chemical products, and, in liquid chromatography, for the purity and reliability of its particulate silica. Merck is not known for its LC columns. Five years after the introduction of its Chromolith line, Merck made a very strategic marketing decision.
Sources: en.wikipedia.org
This species is of typical elongated tetra appearance; it is of plain basic coloration, but with two distinct, adjacent, longitudinal stripes, white above black. The eye has two thin but distinctive color bands across the top, red above yellow. It grows to a maximum overall length of approximately 4 cm (1.6 in). Befitting its common name, it slightly resembles the neon tetra, which belongs to a different genus (Paracheirodon). Females are often larger than males. The variety named Diamond or Brilliant does not have a white stripe but instead displays more reflective scales around the head. The fish's natural diet consists of small invertebrates and plants. H. herbertaxelrodi is commonly kept as an aquarium fish by hobbyists. The black neon tetra is sometimes called the black tetra, but that name more properly refers to a different species, Gymnocorymbus ternetzi.
Ice-T appears in the film Gift. One of the last scenes includes Ice-T and Body Count playing with Jane's Addiction in a version of the Sly and the Family Stone song "Don't Call Me Nigger, Whitey". Besides fronting his own band and rap projects, Ice-T has also collaborated with other hard rock and metal bands, such as Icepick, Motörhead, Megadeth, Pro-Pain, and Six Feet Under. He has also covered songs by hardcore punk bands such as the Exploited, Jello Biafra, and Black Flag. Ice-T made an appearance at Insane Clown Posse's Gathering of the Juggalos (2008 edition). Ice-T was also a judge for the 7th annual Independent Music Awards to support independent artists. His 2012 film Something from Nothing: The Art of Rap features a who's who of underground and mainstream rappers. In November 2011, Ice-T announced via Twitter that he was in the process of collecting beats for his next LP which was expected sometime during 2012, but as of October 2014, the album has not been released. A new Body Count album, Bloodlust, was released in 2017. After the release of the album, responding to an interview question asking if he's "done with rap", he answered "I don't know" and noted that he's "really leaning more toward EDM right now". Body Count received their second Grammy nomination and later won the award at the 63rd Annual Grammy Awards in 2021 for "Best Metal Performance" with their song "Bum-Rush" from the album Carnivore. In July 2019, Ice-T released his first solo hip-hop track in 10 years, titled "Feds in My Rearview".
=== Non refractive roles of crystallins in lens and cornea === While it is evident that gene sharing resulted in many of lens crystallins being multifunctional proteins, it is still uncertain to what extent the crystallins use their non-refractive properties in the lens, or on what basis they were selected. The α-crystallins provide a convincing case for a lens crystallin using its non-refractive ability within the lens to prevent protein aggregation under a variety of environmental stresses and to protect against enzyme inactivation by post-translational modifications such as glycation. The α-crystallins may also play a functional role in the stability and remodeling of the cytoskeleton during fiber cell differentiation in the lens. In cornea, ALDH3 is also suggested to be responsible for absorbing UV-B light.
electron pair Two electrons which occupy the same molecular orbital but have opposite spins. Electron pairs form chemical bonds or occur as lone pairs of valence electrons; it is also possible for electrons to occur individually as unpaired electrons.
Sources: en.wikipedia.org
In July 1991, BOR administered their first Computer adaptive tests the ASCP headquarters for the Medical Technologist (MT), Medical Laboratory Technician (MLT), Phlebotomy Technician (PBT), Cytotechnologist (CT), and Histologic Technician (HT) certification examinations. In 1994, BOR changed their examination format to Computerized adaptive testing (CAT). In 2004, the BOR implemented the Certification Maintenance Program (CMP) requiring continuing education every three years to remain certified.
== Early life == He was born in Fort Worth, Texas, on 15 July 1921, the only son of George E. Merrifield and Lorene née Lucas. In 1923 the family moved to California where he attended nine grade schools and two high schools before graduating from Montebello High School in 1939. It was there that he developed an interest both in chemistry and in astronomy. After two years at Pasadena Junior College he transferred to the University of California at Los Angeles (UCLA). After graduation in chemistry he worked for a year at the Philip R. Park Research Foundation taking care of an animal colony and assisting with growth experiments on synthetic amino acid diets. One of these was the experiment by Geiger using the law of the minimum that first demonstrated that the essential amino acids must be present simultaneously for growth to occur. He returned to graduate school at the UCLA chemistry department with professor of biochemistry M.S. Dunn to develop microbiological methods for the quantitation of the pyrimidines. The day after graduating on 19 June 1949, he married Elizabeth Furlong and the next day left for New York City and the Rockefeller Institute for Medical Research.
==== Bromantane ==== Bromantane is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s. Bromantane acts mainly by facilitating the biosynthesis of dopamine, through indirect genomic upregulation of relevant enzymes (tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD)).
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract. PAMORAs are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, PAMORAs do not affect the analgesic effects of opioids within the central nervous system.
Nihonium at The Periodic Table of Videos (University of Nottingham) Uut and Uup Add Their Atomic Mass to Periodic Table Archived 7 September 2006 at the Wayback Machine Discovery of Elements 113 and 115 Superheavy elements WebElements.com: Nihonium
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.